Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
On July 20, Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc. (HALO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,704,623 | $133,420,842 | -12% | 0.06% |
| 2. | Renaissance Technologies Jim Simons | 479,611 | $37,539,153 | -35% | 0.05% |
| 3. | Fisher Asset Management Ken Fisher | 427,713 | $33,477,096 | -4% | 0.01% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 188,354 | $14,742,467 | +56% | 0.01% |
| 5. | Quantinno Capital Hoon Kim | 166,566 | $13,037,160 | +21% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 17,543 | $249,780.74 | 277,553 | 2020-03-19 | Filing | |
| $14.25 | 17,543 | $249,982.49 | 260,010 | 2020-03-19 | Filing | |
| $14.19 | 17,543 | $248,933.42 | 242,467 | 2020-03-19 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $102.80 | 1,626 | $167,152.80 | 40,418 | 2026-08-10 | Filing | |
| $80.19 | 1,035 | $82,993.55 | 767,780 | 2026-07-08 | Filing | |
| $79.28 | 888 | $70,397.09 | 768,815 | 2026-07-08 | Filing | |
| $77.21 | 625 | $48,255.63 | 42,044 | 2026-07-01 | Filing | |
| $76.40 | 1,000 | $76,395.00 | 42,669 | 2026-07-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,271,095 | $1,038,728,610 | 0.02% | |
| 2. | 5,351,312 | $418,847,190 | 0.01% | |
| 3. | 5,299,008 | $414,753,356 | 0.02% | |
| 4. | 5,179,434 | $405,379,779 | 0.01% | |
| 5. | 2,832,594 | $221,707,309 | 0.01% |
News See All
Q2 Earnings Blowouts: 37 Stocks That Beat Expectations
The ongoing earnings season has been a boon to listed companies' share prices in the second quarter of the year, helping offset macroeconomic uncertainties such as the US-Iran war, global trade, and questions...
8 Most Undervalued Growth Stocks to Buy for the Next 10 Years
Growth stocks aren’t supposed to be cheap. Investors willingly pay higher multiples for companies that are expected to grow earnings over the next few years.
Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best healthcare stocks to buy for the long term. Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript
Operator: At this time, I would like to welcome everyone to Halozyme's First Quarter 2026 Financial and Operating Results Conference Call. Please note, this event is being recorded.
H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook
TheFly reported on April 29 that H.C. Wainwright increased its price objective for HALO to $95 from $90 and reiterated its Buy recommendation on the stock.
10 Best Healthcare Stocks to Buy for the Long Term
On May 7, Haig Bathgate, CEO of Callanish Capital, appeared on CNCB to talk about his bullish view on the global markets amid the Iran war, and how its impact would be short-lived, especially when compared...
10 Best Cancer Stocks to Buy for the Long Term
Pharmaceutical firms have always had a special place in the healthcare market because they provide stability and expansion.
Halozyme (HALO) Rated Buy on Strong Royalty Growth
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now.
10 Most Profitable Biotech Stocks to Buy Now
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, surpassing both the S&P 500 and the broader market index, and ending 2025 with its...